FEMY
Femasys Inc.
Medical - Instruments & Supplies
Market Cap$13M
5Y Perf.-94.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
FEMY vs SSKN
Revenue, margins, valuation, and 5-year total return — side by side.
SSKN
STRATA Skin Sciences, Inc.
Medical - Devices
Market Cap$7M
5Y Perf.-98.9%
FEMY vs SSKN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FEMY | SSKN |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $13M | $7M |
| Revenue (TTM) | $2M | $31M |
| Net Income (TTM) | $-19M | $-11M |
| Gross Margin | 62.0% | 57.8% |
| Operating Margin | -7.7% | -33.3% |
| Total Debt | $5M | $16M |
| Cash & Equiv. | $9M | $7M |
FEMY vs SSKN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FEMY
SSKN
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Femasys Inc. (FEMY) | 100 | 5.5 | -94.5% |
| STRATA Skin Science… (SSKN) | 100 | 1.1 | -98.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FEMY vs SSKN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FEMY leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. STRATA Skin Sciences, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
FEMY
Femasys Inc.
The Growth Play
FEMY carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 40.8%, EPS growth 44.0%, 3Y rev CAGR 23.9%
- -96.3% 10Y total return vs SSKN's -99.6%
- Lower volatility, beta 1.10, Low D/E 80.0%, current ratio 4.53x
Best for: growth exposure and long-term compounding
SSKN
STRATA Skin Sciences, Inc.
The Quality Compounder
SSKN is the clearest fit if your priority is quality and efficiency.
- -35.6% margin vs FEMY's -8.1%
- -35.9% ROA vs FEMY's -116.3%, ROIC -38.9% vs -347.4%
Best for: quality and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FEMY | 40.8% revenue growth vs SSKN's 0.6% |
| Quality / Margins | SSKN | -35.6% margin vs FEMY's -8.1% |
| Stability / Safety | FEMY | Lower D/E ratio (80.0% vs 330.6%) |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | FEMY | -60.6% vs SSKN's -93.3% |
| Efficiency (ROA) | SSKN | -35.9% ROA vs FEMY's -116.3%, ROIC -38.9% vs -347.4% |
FEMY vs SSKN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
FEMY vs SSKN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSSKNLAGGINGFEMY
FEMYFemasys Inc.
1leads
SSKNSTRATA Skin Sciences,…
2leads
6 Total Categories
CATEGORYLEADERvs FEMYMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
SSKN2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SSKN5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
FEMY6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — FEMY and SSKN each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SSKN is the larger business by revenue, generating $31M annually — 13.5x FEMY's $2M. Profitability is closely matched — net margins range from -35.6% (SSKN) to -8.1% (FEMY). On growth, FEMY holds the edge at +39.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | FEMYFemasys Inc. | SSKNSTRATA Skin Scien… |
|---|---|---|
| RevenueTrailing 12 months | $2M | $31M |
| EBITDAEarnings before interest/tax | -$17M | -$5M |
| Net IncomeAfter-tax profit | -$19M | -$11M |
| Free Cash FlowCash after capex | -$19M | -$4M |
| Gross MarginGross profit ÷ Revenue | +62.0% | +57.8% |
| Operating MarginEBIT ÷ Revenue | -7.7% | -33.3% |
| Net MarginNet income ÷ Revenue | -8.1% | -35.6% |
| FCF MarginFCF ÷ Revenue | -8.4% | -11.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +39.9% | -21.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +69.9% | -5.9% |
Evenly matched — FEMY and SSKN each lead in 3 of 6 comparable metrics.
Valuation Metrics
SSKN leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | FEMYFemasys Inc. | SSKNSTRATA Skin Scien… |
|---|---|---|
| Market CapShares × price | $13M | $7M |
| Enterprise ValueMkt cap + debt − cash | $9M | $16M |
| Trailing P/EPrice ÷ TTM EPS | -0.96x | -0.67x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 5.77x | 0.20x |
| Price / BookPrice ÷ Book value/share | 3.03x | 1.34x |
| Price / FCFMarket cap ÷ FCF | — | — |
SSKN leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
SSKN leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
FEMY delivers a -5.3% return on equity — every $100 of shareholder capital generates $-5 in annual profit, vs $-8 for SSKN. FEMY carries lower financial leverage with a 0.80x debt-to-equity ratio, signaling a more conservative balance sheet compared to SSKN's 3.31x. On the Piotroski fundamental quality scale (0–9), SSKN scores 4/9 vs FEMY's 2/9, reflecting mixed financial health.
| Metric | FEMYFemasys Inc. | SSKNSTRATA Skin Scien… |
|---|---|---|
| ROE (TTM)Return on equity | -5.3% | -8.4% |
| ROA (TTM)Return on assets | -116.3% | -35.9% |
| ROICReturn on invested capital | -3.5% | -38.9% |
| ROCEReturn on capital employed | -167.9% | -36.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.80x | 3.31x |
| Net DebtTotal debt minus cash | -$5M | $9M |
| Cash & Equiv.Liquid assets | $9M | $7M |
| Total DebtShort + long-term debt | $5M | $16M |
| Interest CoverageEBIT ÷ Interest expense | -8.85x | -4.63x |
SSKN leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
FEMY leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FEMY five years ago would be worth $374 today (with dividends reinvested), compared to $109 for SSKN. Over the past 12 months, FEMY leads with a -60.6% total return vs SSKN's -93.3%. The 3-year compound annual growth rate (CAGR) favors FEMY at -15.7% vs SSKN's -74.5% — a key indicator of consistent wealth creation.
| Metric | FEMYFemasys Inc. | SSKNSTRATA Skin Scien… |
|---|---|---|
| YTD ReturnYear-to-date | -29.5% | -86.2% |
| 1-Year ReturnPast 12 months | -60.6% | -93.3% |
| 3-Year ReturnCumulative with dividends | -40.1% | -98.3% |
| 5-Year ReturnCumulative with dividends | -96.3% | -98.9% |
| 10-Year ReturnCumulative with dividends | -96.3% | -99.6% |
| CAGR (3Y)Annualised 3-year return | -15.7% | -74.5% |
FEMY leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — FEMY and SSKN each lead in 1 of 2 comparable metrics.
Risk & Volatility
SSKN is the less volatile stock with a -0.24 beta — it tends to amplify market swings less than FEMY's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FEMY currently trades 38.7% from its 52-week high vs SSKN's 4.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FEMYFemasys Inc. | SSKNSTRATA Skin Scien… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | -0.24x |
| 52-Week HighHighest price in past year | $1.16 | $3.86 |
| 52-Week LowLowest price in past year | $0.31 | $0.11 |
| % of 52W HighCurrent price vs 52-week peak | +38.7% | +4.5% |
| RSI (14)Momentum oscillator 0–100 | 57.3 | 41.6 |
| Avg Volume (50D)Average daily shares traded | 513K | 14K |
Evenly matched — FEMY and SSKN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | FEMYFemasys Inc. | SSKNSTRATA Skin Scien… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SSKN leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). FEMY leads in 1 (Total Returns). 2 tied.
Best OverallSTRATA Skin Sciences, Inc. (SSKN)Leads 2 of 6 categories
Loading custom metrics...
FEMY vs SSKN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is FEMY or SSKN a better buy right now?
For growth investors, Femasys Inc.
(FEMY) is the stronger pick with 40. 8% revenue growth year-over-year, versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FEMY or SSKN?
Over the past 5 years, Femasys Inc.
(FEMY) delivered a total return of -96. 3%, compared to -98. 9% for STRATA Skin Sciences, Inc. (SSKN). Over 10 years, the gap is even starker: FEMY returned -96. 3% versus SSKN's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FEMY or SSKN?
By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.
(SSKN) is the lower-risk stock at -0. 24β versus Femasys Inc. 's 1. 10β — meaning FEMY is approximately -553% more volatile than SSKN relative to the S&P 500. On balance sheet safety, Femasys Inc. (FEMY) carries a lower debt/equity ratio of 80% versus 3% for STRATA Skin Sciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — FEMY or SSKN?
By revenue growth (latest reported year), Femasys Inc.
(FEMY) is pulling ahead at 40. 8% versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). On earnings-per-share growth, the picture is similar: Femasys Inc. grew EPS 44. 0% year-over-year, compared to 16. 1% for STRATA Skin Sciences, Inc.. Over a 3-year CAGR, FEMY leads at 23. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — FEMY or SSKN?
STRATA Skin Sciences, Inc.
(SSKN) is the more profitable company, earning -30. 1% net margin versus -812. 3% for Femasys Inc. — meaning it keeps -30. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SSKN leads at -27. 6% versus -767. 0% for FEMY. At the gross margin level — before operating expenses — FEMY leads at 62. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — FEMY or SSKN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is FEMY or SSKN better for a retirement portfolio?
For long-horizon retirement investors, STRATA Skin Sciences, Inc.
(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 24)). Both have compounded well over 10 years (SSKN: -99. 6%, FEMY: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between FEMY and SSKN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: FEMY is a small-cap high-growth stock; SSKN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(FEMY: 39.9% · SSKN: -21.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.